Table 1 Baseline demographics and characteristics in immunocompromised adults
Characteristic | Type of immune-compromising condition, n (%) | |||||
|---|---|---|---|---|---|---|
All (n = 40) | Primary immunodeficiencya (n = 6) | Oncologic immunodeficiencyb (n = 10) | Solid organ transplantc (n = 5) | Hematopoietic cell transplantd (n = 6) | Othere (n = 13) | |
Age, years | ||||||
Mean (SD) | 44.3 (17.4) | 45.2 (14.6) | 43.7 (19.3) | 50.8 (15.2) | 53.3 (18.2) | 37.5 (17.1) |
Median (range) | 41 (18–75) | 48 (29–61) | 46 (18–68) | 49 (35–71) | 61 (24–70) | 37 (18–75) |
Sex | ||||||
Female | 19 (48) | 3 (50) | 4 (40) | 2 (40) | 2 (33) | 8 (62) |
Male | 21 (53) | 3 (50) | 6 (60) | 3 (60) | 4 (67) | 5 (38) |
Race | ||||||
White | 25 (63) | 4 (67) | 7 (70) | 5 (100) | 2 (33) | 7 (54) |
Hispanic/Latino | 4 (10) | 0 | 2 (20) | 0 | 0 | 2 (15) |
Black/African American | 5 (13) | 1 (17) | 1 (10) | 0 | 2 (33) | 1 (8) |
Asian | 2 (5) | 0 | 0 | 0 | 1 (17) | 1 (8) |
Unknown/Not reported | 4 (10) | 1 (17) | 0 | 0 | 1 (17) | 2 (15) |
Location of VZV exposure | ||||||
Household | 21 (53) | 5 (83) | 5 (50) | 1 (20) | 3 (50) | 5 (38) |
Healthcare setting | 16 (40) | 0 | 4 (40) | 4 (80) | 3 (50) | 7 (54) |
School | 1 (2) | 0 | 0 | 0 | 0 | 1 (8) |
Unknown | 2 (5) | 1 (17) | 1 (10) | 0 | 0 | 0 |
Type of VZV exposure | ||||||
Varicella | 19 (48) | 3 (50) | 7 (70) | 1 (20) | 1 (17) | 7 (54) |
Herpes zoster | 15 (38) | 2 (33) | 1 (10) | 4 (80) | 4 (67) | 4 (31) |
Unknown/not specifiedf | 6 (15) | 1 (17) | 2 (20) | 0 | 1 (17) | 2 (15) |
Timing of VARIZIG administration | ||||||
< 96 h after exposure | 32 (80) | 5 (83) | 9 (90) | 3 (60) | 5 (83) | 10 (77) |
5–10 days after exposure | 8 (20) | 1 (17) | 1 (10) | 2 (40) | 1 (16) | 3 (23) |